Pinned Tweet
The first evidence of in vivo SARS-CoV-2 escape from antibodies: emergent Spike deletion H69/V70 and D796H mutation in a convalescent plasma (CP) treated patient. These mutations conferred reduced susceptibility to the CP and sera from multiple donors. medrxiv.org/content/10.1101/…
Gupta Lab retweeted
Long thread on bioRxiv paper co-authored with #ListerFellow @GuptaR_lab. New mutation patterns in SARS-CoV-2 from patients with chronic infection. Evidence of CD8 T cell-escape and adaptation to tissue compartments outside the upper-respiratory tract. biorxiv.org/content/10.64898…
Gupta Lab retweeted
#2: Mutations overrepresented in chronic seqs (relative to circulating seqs) are almost certainly functionally meaningful—e.g. Ab evasion, T-cell evasion, or adaptation to a tissue type.
See new preprint by me, Darren Martin, & @GuptaR_lab on this.
biorxiv.org/content/10.64898…
7/
Gupta Lab retweeted
Once again, for those not already aware, clinical academics contribute to both the health and wealth of the UK. We need to be supporting them and growing their number not hastening their extinction.
#ClinicalAcademicCrisis
Gupta Lab retweeted
Wonderful and exciting week here in Hong Kong for #NIDO2026 talking about Nidoviruses and pandemic/epidemic preparedness.
Exciting times ahead utilising all resources available to generate critical evidence to inform practice!
@hkjcghi @GuptaR_lab @MedCambridge
Meeting old and new colleagues in humid Hong Kong #nidovirus 2026. 3 talks from our lab today and one more to come from me at the GHI session. however, the team already presented most of the cool data👀. Time to zoom out for a global perspective! @hkjcghi
Gupta Lab retweeted
Finally finished a long-gestating paper on mutation patterns in chronic infections (with co-authors Darren Martin & @GuptaR_lab) & it's now available in preprint form.
Paper too long for 1 summary 🧵, but I'll do a cursory overview now, then 🧵s on subsections later.
1/16
Gupta Lab retweeted
Another exciting day at #NidoVirus2026 with talks by great labs @GuptaR_lab @SystemsVirology @Lab_Rihn_th @weisssr @lucygthorne a
@CEPIvaccines and more...
Meeting old and new colleagues in humid Hong Kong #nidovirus 2026. 3 talks from our lab today and one more to come from me at the GHI session. however, the team already presented most of the cool data👀. Time to zoom out for a global perspective! @hkjcghi
Our superstar Bo Meng delivering a killer talk on adaptation of SARS CoV 2 to use surface heparan sulphate for cell entry +tropism using primary human tissues and live viruses. a complex story delivered with clarity and precision during the #Nido2026 entry session
Super excited to be at the Nidovirus meeting in HK. We will be discussing CoV amongst others over the coming days @hkjcghi
Gupta Lab retweeted
Join the #HKJCGHI Sharing Session at #NIDO2026 to explore pandemic preparedness & the latest SARS‑CoV‑2 research with leading experts.
More: nido2026.com
Wow just heard about new clinical trials of a new drug for hep B infection at the European HIV hepatitis meeting - antisense oligo nucleotides showing promising results in those already taking nucleotide/side inhibitors. And for hep D a new entry inhibitor.@hkjcghi @MedCambridge
Back to my HIV routes at the 4th European Meeting on HIV & Hepatitis in Barcelona, catching up with giants in the field of HIV drug resistance. Mpox on the menu here too and we look forward to soon sharing our data on mpox vaccine in people living with HIV. @hkjcghi
Gupta Lab retweeted
Japan: "COVID-19 still kills over 30,000 a year, even 3 years since the infectious disease was downgraded to the level of seasonal influenza"
🔹36,000 COVID deaths in 2024
🔹38,000 COVID deaths in 2023
COVID-19 was 8th cause of death in Japan, 2023-2024
asahi.com/ajw/articles/16560…
Very concerned about the state of final preparedness in light of New Ebola outbreak and hantavirus cruise ship incident. We are committed @hkjcghi and @MedCambridge to addressing preparedness against a range of pathogens, but funding needs to step up in a consistent way.











































